Scarica l'app Stockscreener
3.42
0.88%
0.03
Dopo l'orario di chiusura:
3.43
0.01
+0.29%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$3.39
Aprire:
$3.33
Volume 24 ore:
42,941
Relative Volume:
0.22
Capitalizzazione di mercato:
$138.33M
Reddito:
$2.00M
Utile/perdita netta:
$63.21M
Rapporto P/E:
2.3026
EPS:
1.4853
Flusso di cassa netto:
$-9.71M
1 W Prestazione:
+3.01%
1M Prestazione:
+2.40%
6M Prestazione:
+36.05%
1 anno Prestazione:
+55.45%
Intervallo 1D:
$3.3064
$3.44
Intervallo di 1 settimana:
$3.23
$3.52
Portata 52W:
$1.82
$3.76
Oramed Pharmaceuticals Inc Stock (ORMP) Company Profile
Nome
Oramed Pharmaceuticals Inc
Settore
Industria
Telefono
646-844-1164
Indirizzo
1185 AVENUE OF THE AMERICAS, 3RD FLOOR, NEW YORK, NY
Compare ORMP vs VRTX, REGN, ARGX, ALNY, INSM
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ORMP
Oramed Pharmaceuticals Inc
|
3.42 | 138.33M | 2.00M | 63.21M | -9.71M | 1.4853 |
VRTX
Vertex Pharmaceuticals Inc
|
438.71 | 111.45B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
761.85 | 80.54B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
746.42 | 46.32B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
318.85 | 42.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
INSM
Insmed Inc
|
162.43 | 35.01B | 606.42M | -1.28B | -997.58M | -6.403 |
Oramed Pharmaceuticals Inc Stock (ORMP) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2023-01-12 | Downgrade | Canaccord Genuity | Buy → Hold |
| 2022-02-18 | Iniziato | Cantor Fitzgerald | Overweight |
| 2021-04-20 | Iniziato | Canaccord Genuity | Buy |
| 2021-02-09 | Iniziato | National Securities | Buy |
| 2020-12-03 | Iniziato | Alliance Global Partners | Buy |
| 2020-03-11 | Iniziato | Aegis Capital | Buy |
| 2019-09-11 | Iniziato | Ladenburg Thalmann | Buy |
| 2017-12-11 | Ripresa | B. Riley FBR, Inc. | Buy |
| 2016-05-26 | Reiterato | FBR Capital | Outperform |
| 2015-12-01 | Reiterato | H.C. Wainwright | Buy |
| 2015-11-19 | Iniziato | FBR Capital | Outperform |
| 2015-04-13 | Ripresa | MLV & Co | Buy |
| 2014-01-30 | Reiterato | Aegis Capital | Buy |
| 2014-01-08 | Reiterato | Aegis Capital | Buy |
| 2014-01-08 | Iniziato | MLV & Co | Buy |
| 2013-12-03 | Iniziato | Aegis Capital | Buy |
Mostra tutto
Oramed Pharmaceuticals Inc Borsa (ORMP) Ultime notizie
ORMP Earning Date, Earning Analysis and Earning Prediction - Intellectia AI
Oramed Pharmaceuticals stock: Oral insulin pioneer or high-risk bet? - AD HOC NEWS
ORMP Should I Buy - Intellectia AI
ORMP Price History for Oramed Pharma Stock - Barchart.com
Oramed Completes Oratech Sale and Strategic Lifeward Financing - The Globe and Mail
ABOS Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Oramed (ORMP) completes Oratech sale and buys $9M Lifeward notes - Stock Titan
Oramed (NASDAQ: ORMP) CSO uses 435,084 shares to cover RSU tax - Stock Titan
Oramed (NASDAQ: ORMP) CEO uses 44,818 shares to cover RSU tax withholding - Stock Titan
FOMO Trade: Is Oramed Pharmaceuticals Inc stock good for income investorsMarket Sentiment Report & Entry and Exit Point Strategies - baoquankhu1.vn
Oramed Pharmaceuticals (ORMP) price target increased by 92.31% to 6.38 - MSN
Oramed Pharmaceuticals (NASDAQ:ORMP) Posts Quarterly Earnings Results, Beats Expectations By $0.02 EPS - MarketBeat
Oramed Pharmaceuticals: Oral Insulin Technology, Strategic Investments, and 2026 Business Overview - Minichart
Oramed: Q4 Earnings Snapshot - Barchart.com
Oramed Pharmaceuticals 2025 10-K: $2.0M Revenue, $1.50 Diluted EPS - TradingView
Oramed (NASDAQ: ORMP) pivots with Lifeward deal and Alpha Tau stake - Stock Titan
Lifeward closes Oramed partnership, secures $10 million funding By Investing.com - Investing.com Australia
Lifeward Closes Oramed Partnership, Acquires Oratech Pharma - Moomoo
Lifeward closes Oramed partnership, secures $10 million funding - Investing.com
Lifeward Successfully Closes on Strategic Partnership with Oramed - manilatimes.net
Lifeward Ltd. completed the acquisition of Oratech Pharma, Inc. from Oramed Pharmaceuticals Inc.. - MarketScreener
12 Health Care Stocks Moving In Monday's After-Market Session - Benzinga
Oramed Pharmaceuticals Inc expected to post breakeven results a shareEarnings Preview - TradingView
Surprises Report: Does Oramed Pharmaceuticals Inc stock benefit from AI growth2026 Macro Impact & Pattern Based Trade Signal System - baoquankhu1.vn
Oramed Pharmaceuticals (ORMP) to Release Earnings on Thursday - MarketBeat
Market Overview: What is Oramed Pharmaceuticals Incs 5 year growth outlookEarnings Growth Report & High Accuracy Swing Entry Alerts - baoquankhu1.vn
[Form 4] ORAMED PHARMACEUTICALS INC. Insider Trading Activity - Stock Titan
Oramed (NASDAQ: ORMP) CEO receives 167,005 RSUs vesting from 2026 - Stock Titan
Oramed (NASDAQ: ORMP) COO receives 95,889 RSUs vesting from 2026 - Stock Titan
Oramed (NASDAQ: ORMP) CFO receives 95,889 RSU equity award - Stock Titan
Oramed deal reshapes Lifeward (NASDAQ: LFWD) with new tech and funding - Stock Titan
Oral insulin and robotic exoskeletons: Lifeward’s $47M pivot - Stock Titan
Retail Trends: How sensitive is Oramed Pharmaceuticals Inc to inflationWeekly Trade Recap & Low Risk Entry Point Guides - baoquankhu1.vn
Is Oramed Pharmaceuticals Inc stock undervalued right nowEarnings Risk Report & Verified Momentum Watchlists - baoquankhu1.vn
Returns Recap: Is Oramed Pharmaceuticals Inc stock a smart retirement pickMarket Volume Report & High Yield Stock Recommendations - baoquankhu1.vn
Oramed (ORMP) CEO donates 100,000 shares to charity - Stock Titan
Lifeward shareholders approve Oramed partnership deal By Investing.com - Investing.com India
Lifeward shareholders approve Oramed partnership deal - Investing.com
Lifeward Partners with Oramed to Enhance Biotech Portfolio and Drive Path to Profitability - Quiver Quantitative
Lifeward Receives Shareholder Approval to Close on - globenewswire.com
Lifeward Receives Shareholder Approval to Close on Strategic Partnership with Oramed—Creating Diversified Biomedical Company - Yahoo Finance
LFWD Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
Gains Report: What is the target price for Oramed Pharmaceuticals Inc stockChart Signals & Consistent Return Investment Signals - baoquankhu1.vn
Lifeward Receives Shareholder Approval to Close on Strategic Partnership with Oramed-Creating Diversified Biomedical Company - Bitget
Aug PreEarnings: What is Oramed Pharmaceuticals Incs 5 year growth outlookWeekly Profit Recap & Expert Curated Trade Setups - baoquankhu1.vn
Oramed Pharmaceuticals (ORMP) Leads Healthcare Dividend Yields - GuruFocus
Top 10 healthcare stocks with highest dividend yield amid volatile markets (ORMP:NASDAQ) - Seeking Alpha
DYCQ Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
Dip Buying: Is Oramed Pharmaceuticals Inc stock a smart retirement pick2025 Growth vs Value & Safe Entry Trade Signal Reports - baoquankhu1.vn
Update Report: Can Oramed Pharmaceuticals Inc maintain sales growthShare Buyback & Accurate Buy Signal Alerts - baoquankhu1.vn
ORMP Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Oramed Pharmaceuticals Inc Azioni (ORMP) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.49%
1.47%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):